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Abstract
Introduction The metastatic progression of cancer is a direct
result of the disregulation of numerous cellular signaling
pathways, including those associated with adhesion, migration,
and invasion. Members of the Rac family of small GTPases are
known to act as regulators of actin cytoskeletal structures and
strongly influence the cellular processes of integrin-mediated
adhesion and migration. Even though hyperactivated Rac
proteins have been shown to influence metastatic processes,
these proteins have never been directly linked to metastatic
progression.
Methods To investigate a role for Rac and Cdc42 in metastatic
breast cancer cell invasion and migration, relative endogenous
Rac or Cdc42 activity was determined in a panel of metastatic
variants of the MDA-MB-435 metastatic human breast cancer
cell line using a p21-binding domain-PAK pull down assay. To
investigate the migratory and invasive potential of the Rac
isoforms in human breast cancer, namely Rac1 and the
subsequently cloned Rac3, we stably expressed either
dominant active Rac1 or dominant active Rac3 into the least
metastatic cell variant. Dominant negative Rac1 or dominant
negative Rac3 were stably expressed in the most metastatic cell
variant. Cell lines expressing mutant Rac1 or Rac3 were
analyzed using in vitro adhesion, migration and invasion assays.
Results We show that increased activation of Rac proteins
directly correlates with increasing metastatic potential in a panel
of cell variants derived from a single metastatic breast cancer
cell line (MDA-MB-435). The same correlation could not be
found with activated Cdc42. Expression of a dominant active
Rac1 or a dominant active Rac3 resulted in a more invasive and
motile phenotype. Moreover, expression of either dominant
negative Rac1 or dominant negative Rac3 into the most
metastatic cell variant resulted in decreased invasive and motile
properties.
Conclusion This study correlates endogenous Rac activity with
high metastatic potential and implicates Rac in the regulation of
cell migration and invasion in metastatic breast cancer cells.
Taken together, these results suggest a role for both the Rac1
and Rac3 GTPases in human breast cancer progression.
Introduction
Cancer metastasis is a multi-faceted process requiring the dis-
regulation of numerous signaling pathways, including those
associated with cell adhesion and motility. The initial steps of
metastasis require the acquisition of a motile phenotype in
order to traverse tissue boundaries, while the later stages
require dynamic adhesive interactions with the extracellular
matrix to facilitate the extravasation of malignant cells [1]. Acti-
vation of the Rho family GTPases Rac and Cdc42 is a critical
event in the integrin and growth factor-mediated regulation of
cellular migration and adhesion, implicating the hyperactiva-
tion of these proteins in the progression of metastatic disease
[2].
Activation of Rac and Cdc42 is critical for initiating cell motility
and adhesion via the dynamic turnover of cell-substratum
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contacts (focal adhesions) and the nucleation of actin mono-
mers necessary for the assembly of actin filaments required for
cell movement [2]. Activation of the appropriate levels of these
proteins, together with temporal and spatial coordination,
must be precisely regulated to achieve normal cellular function
[3]. Aberrant Rac and Cdc42 activities have been recently
associated with invasive and malignant behavior in a variety of
cell types, including hepatocarcinoma, breast carcinoma, and
melanoma [4-6]. Breast tissue sample analysis has demon-
strated, however, that the contribution of the Rac and Cdc42
proteins to tumor cell invasion in breast cancer is not due to
genetic mutation, but is due instead to changes in the activity
levels of these proteins caused by hyperactivation of upstream
activators [3,7]. Yet, a direct correlation between Rac and
Cdc42 protein activity states and metastatic progression in
human breast cancer remains to be demonstrated.
The Rac subfamily includes Rac1, the myeloid-lineage specific
Rac2, and the subsequently cloned Rac3 protein [8]. Exhibit-
ing an 89% and 92% identity to Rac1 and Rac2, respectively,
Rac3 differs from other Rac proteins only in the carboxyl termi-
nus, a region essential for subcellular localization and regula-
tory protein binding [8,9]. In fact, differential localization of
Rac1 and Rac3 has been demonstrated in the developing
mammalian brain [10]. Moreover, dominant activation of Rac3
in the mammary epithelium has been shown to lead to the for-
mation of mammary lesions [11], although a direct role for
Rac3 in breast cancer invasion and metastasis has yet to be
substantiated.
To further understand the molecular mechanisms of the small
GTPases Rac and Cdc42 in human breast cancer, we used a
panel of cell variants, isolated from the MDA-MB-435 human
metastatic breast cancer cell line, that varied in their ability to
form secondary pulmonary and cerebral lesions in the nude
mouse model of experimental metastasis [12]. Within this
panel, we found a direct correlation between the invasive phe-
notype, enhanced migratory ability, and increased metastatic
potential. Moreover, we found that increased Rac, but not
Cdc42, activation correlated with increased metastatic
potential.
Previously, Rac1 was shown to play a critical role in rat mam-
mary tumor cell growth and metastasis in vivo [5]. To establish
a role for both Rac1 and Rac3 in human breast cancer, we car-
ried out a comparative study of the invasive capabilities
between the two isoforms. Dominant active Rac1 or Rac3
mutants were expressed in the least metastatic cell variant of
our panel, and dominant negative Rac1 or Rac3 mutants were
expressed in the most metastatic cell variant. Dominant active
Rac expression of either isoform resulted in an aggressive
phenotype, as well as significant increases in adhesion to
extracellular matrix, migration, and invasion through basal lam-
ina. Conversely, dominant negative expression of either iso-
form resulted in significant decreases in adhesion to
extracellular matrix, migration, and invasion. Taken together,
these data suggest a direct role for both Rac1 and Rac3 pro-
tein activation in the metastatic progression of human breast
cancer.
Materials and methods
Cell culture
The human breast cancer cell line variants MDA-MB-
435α6HG6, MDA-MB-435, MDA-MB-435α6LF9, and MDA-
MB-435Br1 were cultured in Dulbecco's modified Eagle's
medium (Gibco™, Carlsbad, CA, USA) with 10% v/v FBS (Tis-
sue Culture Biologicals, Tulare, CA, USA) and cultured in a
humidified 5% CO2 atmosphere at 37°C.
DNA constructs and transfections
Rac1 mutant cDNA (Myc-Rac1(G12V) and Myc-Rac1(T17N))
were generous gifts from Dr Gary Bokoch of the Scripps Insti-
tute (La Jolla, CA, USA). Rac3 mutant cDNA (Myc-
Rac3(G12V) and Myc-Rac3(T17N)) were generous gifts from
Dr Ulla Knaus of the Scripps Institute (La Jolla, CA, USA).
Mutant Rac cDNAs were digested out of the pRK5myc vector
and inserted into the multiple cloning site of the pIRESneo2
vector (Clontech, Mt. View, CA, USA). pIRESneo2 vector
alone, or vectors encoding myc-tagged Rac1(G12V),
Rac1(T17N), Rac3(G12V), or Rac3(T17N) were transfected
into cell variants using Lipofectamine Plus Reagent (Gibco™).
Maximal expression was achieved 24 to 48 h post transfection
with a transfection efficiency of approximately 70% at 48 h, as
monitored by staining for myc expression. All experiments
were conducted at 36 h following transfection and confirmed
using stable cell lines.
Immunofluorescence microscopy
Cells cultured on glass coverslips were fixed in 3.7% formal-
dehyde (Sigma Chemical Corp., St. Louis, MO, USA), perme-
ablized with 0.5% Triton X-100 (Sigma Chemical Corp.), and
blocked with 5% goat serum (Gibco™) and 5% BSA (Sigma
Chemical Corp.). Cells were then stained with rhodamine
phalloidin (Molecular Probes, Eugene, OR, USA) to visualize
F-actin, and a mouse monoclonal anti-phosphorylated tyrosine
antibody, clone 4G10 (Upstate Biotechnology, Waltham, MA,
USA), followed by fluorescein isothyocianate (FITC)-conju-
gated goat anti-mouse IgG (ICN Biomedicals Inc., Irvine, CA,
USA) as in [13]. Cells were imaged with either an Olympus
(Hamburg, Germany) upright fluorescence microscope or a
Zeiss (Thornwood, NY, USA) inverted confocal microscope
with fluorescence and DIC (Differential Interference Contrast)
capabilities. Images were overlayed with Spot Advanced dig-
ital camera software (Diagnostic Instruments Inc., Sterling
Heights, MI, USA).
Adhesion assays
Cell adhesion assays were performed according to Klemke et
al. [14]. Briefly, glass coverslips (Fisher Scientific, Pittsburg,
PA, USA) were coated with laminin (Gibco BRL, Carlsbad,Available online http://breast-cancer-research.com/content/7/6/R965
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CA, USA). Proteins were allowed to bind overnight at 4°C
before the coverslips were blocked for 1 h with 1% w/v heat-
denatured BSA (Sigma Chemical Corp.) in 1× PBS. Cells
(105) were added to the wells and allowed to adhere for 15
minutes. Non-adherent cells were removed, and the adherent
cells were fixed in 3.7% formaldehyde (Sigma Chemical
Corp.). The number of cells per microscopic field for 30 fields
per coverslip was counted with an Olympus upright micro-
scope with a 40× phase contrast objective. Non-specific cell
adhesion as measured on BSA-coated coverslips has been
subtracted. Effects of the ectopic expression of Rac mutants
were assessed 36 to 48 h post transfection.
Haptotaxis migration and invasion assays
Cell migration and invasion assays were performed as
described in Klemke et al. [14]. Briefly, modified Boyden
chambers (tissue culture treated, 6.5 mm diameter, 10 µm
thickness, 8 µm pores, Transwell®, Costar Corp., Cambridge,
MA, USA) containing polycarbonate membranes were coated
with matrigel (Fisher Scientific) or laminin (Gibco BRL) on the
underside of the membrane (migration), or the upperside of
the membrane (invasion). For invasion assays, cells chemo-
tracted to media supplemented with 10% v/v FBS (Tissue
Culture Biologicals). Serum starved cells (106 cells) were
added to the upper surface of each migration chamber and
allowed to migrate to the underside of the membrane for 4 h
(migration) or 24 h (invasion). The non-migratory cells on the
upper membrane surface were removed, and the migratory
cells attached to the bottom surface of the membrane were
stained with propidium iodide (PI) (CalBioChem-Novabio-
chem Corp., San Diego, CA, USA). For PI staining, cells were
fixed and permeablized in 70% ethanol and then incubated
Figure 1
Characterization of cytoskeletal structures and focal adhesion distribution in MDA-MB-435 metastatic variants Characterization of cytoskeletal structures and focal adhesion distribution in MDA-MB-435 metastatic variants. (a) Each of the MDA-MB-435 meta-
static variants was plated onto glass coverslips. Actin was visualized with rhodamine phalloidin and focal adhesions were visualized with an anti-p-
tyro antibody followed by an FITC conjugated secondary antibody. (b) Cell area was measured on 50 individual cells per variant using Spot Digital 
Camera Software. Focal adhesion number was divided by cell area and plotted on the y-axis. Bars represent ±SEM, and are representative of three 
independent experiments. Treatments denoted by the same letter indicate no significant difference between those treatments. Treatments denoted 
by different letters indicate a significant difference between those treatments (P < 0.01).Breast Cancer Research    Vol 7 No 6    Baugher et al.
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with 40 µg/ml PI in 1× PBS. The number of migratory cells per
30 microscopic fields per membrane was counted with an
Olympus upright fluorescence microscope with a 40× objec-
tive for migration assays and a 10× objective for invasion
assays. Non-specific migration as measured on chambers with
no chemoattractant has been subtracted. Effects of the
ectopic expression of Rac mutants were assessed 36 to 48 h
post transfection.
Rac and Cdc42 activity assays
For guanine nucleotide binding, cell lysates were incubated for
15 minutes at 30°C in the presence of 10 mM EDTA and 100
µM GTPγS (Roche, Rockford, IL, USA) or 1 mM GDP (Sigma)
to facilitate nucleotide exchange as described in Knaus et al.
[15]. The loading reaction was stopped by the addition of
MgCl2.
Rac and Cdc42 activity assays were performed as described
in [16] with minor modifications. Briefly, cells were lysed
directly in their 10 cm plates (Fisher Scientific) with ice cold
lysis buffer. Lysates were then incubated at 4°C with 10 µg of
PAK-PBD Protein GST Beads (Cytoskeleton Inc., Denver,
CO, USA). The bead pellet was washed once with buffer con-
taining 1% Nonidet P-40 (Calbiochem, San Diego, CA, USA),
twice without Nonidet P-40, and suspended in 20 µl Laemelli
sample buffer. Proteins from the total cell lysate, as well as the
bead pellet, were separated by 10% SDS-PAGE gel, trans-
ferred to a nitrocellulose membrane, and blotted for the appro-
priate GTPase using a monoclonal anti-Rac antibody (clone
32A8; Upstate Biotechnology) or a mouse monoclonal anti-
Cdc42 antibody (clone 44; Transduction Laboratories, San
Diego, CA, USA). Immunoblots were detected with the Super-
Signal West Femto-Substrate chemiluminescence kit (Pierce
Endogen, Rockford, IL, USA) and Kodak Biomax MR film
(Fisher Scientific).
Toxin B Inhibition
Clostridium difficile toxin B was purchased from Calbiochem
and used as described in [17,18]. Cells were treated with 2
ng/ml toxin B for 24 h before being subjected to haptotaxis
assay. These were the conditions required for suppression of
all Rho GTPase activity while maintaining 95% cell viability.
Statistical analysis
Data are expressed as means ± standard error of the mean
(SEM). P-values were calculated from unpaired or paired t-
tests using Microsoft Excel (Microsoft Corp., Redmond WA,
USA) and considered significant at p-values less than 0.05.
Results
Cytoskeletal and migratory phenotype of MDA-MB-435 
metastatic variants correlates with metastatic efficiency
To understand the role of the Rho GTPases in metastatic
breast cancer, we selected variants of the MDA-MB-435 met-
astatic breast cancer cell line and cycled them through the
nude mouse model of experimental metastasis. The variants
studied were chosen based on their ability to metastasize from
tumors in the mammary fatpad to distant organs, predomi-
nantly lungs and lymph nodes. The MDA-MB-435α6HG6 var-
iant produced the highest number of distant metastases from
primary mammary tumors, followed by the parental MDA-MB-
435, then MDA-MB-435α6LF9, and finally MDA-MB-435Br1.
The MDA-MB-435Br1 cell line readily forms experimental
brain metastases following injection into the intra-carotid
artery, yet it shows significantly lower ability to metastasize in
the more stringent assay of spontaneous metastasis [12].
An invasive cellular phenotype can be indicative of metastatic
behavior [14]. Rac-induced membrane ruffles, or lamellipodia,
have been shown not only to be important structures in cellular
motility, but have also been shown to play a key role in invasion
with respect to metastatic progression [2,19,20]. Rac-
induced lamellipodia contain many cell-substratum contacts,
or focal adhesions. Aberrant focal adhesion expression has
been associated with malignant progression [21]. Therefore,
we investigated the correlation between cytoskeletal pheno-
type and metastatic efficiency. Our data show a direct correla-
Figure 2
Haptotaxis assays of MDA-MB-435 metastatic variants Haptotaxis assays of MDA-MB-435 metastatic variants. Each variant 
was adjusted to 500,000 cells and applied to Transwell chambers in a 
haptotaxis assay, where the underside of the membrane was coated 
with matrigel. Cells migrating to the underside of the chamber were 
stained with propidium iodide and counted under 400× Magnification. 
Bars represent ±SEM. Data are representative of three independent 
experiments. Treatments denoted by the same letter indicate no signifi-
cant difference between those treatments. Treatments denoted by dif-
ferent letters indicate a significant difference between those treatments 
(P < 0.01, calculated from unpaired t-test).Available online http://breast-cancer-research.com/content/7/6/R965
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tion between high lamellipodia expression and increased
metastatic efficiency (Fig. 1a). The most metastatic variant,
MDA-MB-435α6HG6, exhibits a strikingly different phenotype
than the other variants, including an increased number of focal
adhesions and a cross-linked actin network. In fact, we found
that increased focal adhesion expression correlates with
increased metastatic efficiency in all cell variants (Fig. 1b).
However, individual MDA-MB-435α6HG6 (most metastatic)
cells were 1.5 times larger than other variants (data not
shown). Thus, the data were compiled as focal adhesions per
cell area (Fig. 1c). This correlation between lamellipodia, focal
adhesions, and metastatic potential strongly suggests an
enhanced invasive and motile phenotype correlates with
increased metastatic efficiency.
Subsequent to the epithelial to mesenchymal transition, cells
must first migrate away from the primary tumor through the
basal lamina to begin the process of establishing sites of sec-
ondary tumor formation. Therefore, increased cell migration in
malignant cells is thought to be closely linked to invasion and
metastasis [1,2]. Upon investigation into the migratory behav-
ior of the cell variants, we found a correlation between
increased metastatic potential and increased migration (Fig.
2).
Increased Rac activity can be correlated with MDA-MB-
435 metastatic variants
Increases in activity levels of the Rho proteins Rac and Cdc42
have been shown to be accountable for the promotion of
tumor cell invasiveness [3,7]. Therefore, we investigated the
Rac and Cdc42 activity levels in all MDA-MB-435 metastatic
variants. To determine the relative amounts of activated Rac
and Cdc42 in the variant panel, we used Rac and Cdc42
activity assays [16]. Whereas total endogenous Rac protein
expression remains equal among the cell variants, levels of
Rac protein activity ranged from being highest in the most met-
astatic variant, medium in parental and medium metastatic var-
iants, to least active in the least metastatic variant (Fig. 3a).
Loading cell lysates with a non-hydrolyzable GTP analog,
GTPγS, showed a relatively equal GTP-binding capacity of the
Rac protein among the four variants. Therefore, all Rac
expressed in the variants of the metastatic panel can poten-
tially be activated to the same extent. Thus, endogenous acti-
vators of Rac appear to have increased activity in the more
metastatic cell variants. Endogenous Cdc42 protein expres-
sion differed slightly among the variants; the more metastatic
variants expressed slightly higher levels of endogenous
Cdc42 than the less metastatic variants (Fig. 3b). However, no
active Cdc42 protein could be detected. Again, GTPγS load-
ing showed the ability of the Cdc42 proteins to bind GTP and
become active.
Inhibition of Rho GTPase activity suppresses invasive 
potential of MDA-MB-435 cells
Because the Rho family of small GTPases, namely Rho, Rac,
and Cdc42, are essential to cell motility, we used Clostridium
difficile toxin B to inhibit the Rho family in these cell variants.
Toxin B was used as described in [17,18]. Inhibition of Rho
GTPases by incubation in 2 ng/ml toxin B for 16 h demon-
strated the expected attenuation of Rac-induced lamellipodia
in response to epidermal growth factor. Subsequent to treat-
ment with toxin B, the most metastatic variant, MDA-MB-
435α6HG6, exhibited a 50% decrease in migration to basal
lamina, and the others exhibited a definite decrease in migra-
tion, although not as striking (Fig. 4a). Therefore, increased
migration in the most metastatic variant appears to be regu-
lated in part by the Rho family of small GTPases.
Hyperactive Cdc42 has been implicated in tumor cell invasion
due to its effects on the actin cytoskeleton [5,20]. To deter-
mine a role for Cdc42 in the migration of highly metastatic
cells, we expressed vector alone and a dominant negative
Figure 3
Rac and Cdc42 activity in MDA-MB-435 metastatic variants Rac and Cdc42 activity in MDA-MB-435 metastatic variants. Whole cell lysates of all variants were subjected to SDS-PAGE followed by western 
blot analysis for (a) total Rac using an anti-Rac antibody and (b) total Cdc42 using an anti-Cdc42 antibody. Rac and Cdc42 activities were assayed 
using the PAK-PBD activity assay. A non-hydrolyzable GTP analog, GTPγS, was used as the positive control; GDP alone was used for the negative 
control. Equal loading of lanes was maintained by performing a total protein assay and is confirmed by western blot analysis for total actin. Results 
are representative of three to five independent experiments.Breast Cancer Research    Vol 7 No 6    Baugher et al.
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myc-tagged Cdc42(T17N) construct in the highly metastatic
MDA-MB-435α6HG6 cell variant and subjected both to a
migration assay. We found that expression of Cdc42(T17N)
did not inhibit migration compared to the vector alone control
(Fig. 4b). However, when we expressed vector alone, domi-
nant negative Rac1(T17N), or dominant negative
Rac3(T17N), we found a significant inhibition of migration
compared to the vector control (Fig. 4c). Therefore, Rac activ-
ity appears to be essential for the migration of highly meta-
static cells, but Cdc42 activity does not.
Ectopic Rac(G12V) expression augments the invasive 
phenotype of low metastatic breast cancer cells
Invasive malignant cell morphology includes an increased
number of focal adhesions, as well as an increase in actin
structures such as cross-linked actin fibers and membrane ruf-
fles [1,2]. The morphology of the low metastatic cell variant
MDA-MB-435Br1 when expressing vector alone is indicative
of a less invasive cell. Actin fibers are not cross-linked, lamel-
lipodia are limited to the proximal and distal ends of the cell,
and focal adhesions are few (Fig. 5). Conversely, MDA-MB-
435Br1 cells expressing myc-tagged Rac1(G12V) or
Rac3(G12V) exhibit cross-linked actin fibers, numerous focal
adhesions, and lamellipodia expressed ubiquitously around
the periphery of the cell (Fig. 5). Expression of either myc-
tagged Rac1(T17N) or Rac3(T17N) in the highly metastatic
MDA-MB-435α6HG6 variant resulted in a slight decrease in
focal adhesion number and size of lamellipodia compared to
the vector alone control (data not shown). Expression of dom-
inant negative Cdc42(T17N) in the same cell variant resulted
in no significant alteration of phenotype compared to the vec-
tor alone control (data not shown).
Rac mutants significantly alter cellular processes 
essential to metastatic behavior
Because metastatic progression results from increased migra-
tion of malignant cells out of the basal lamina, subsequent
adhesion to the extracellular matrix, and final invasion into dis-
tant tissues to establish secondary sites of metastasis, we
measured the effect of Rac mutants on these processes in
vitro. For each of these assays, cells expressed equal amounts
of activated Rac1 or Rac3 mutant protein (data not shown).
Recent data indicate that changes in cell adhesion play a crit-
ical role in tumor progression [21]; thus, we tested the ability
of Rac mutants to alter adhesive properties of malignant cells
in vitro. Expression of dominant active Rac1(G12V) or
Rac3(G12V) causes a significant increase in adhesion to
basal lamina when expressed in the low metastatic MDA-MB-
435Br1 variant compared to the vector alone control, whereas
dominant negative Rac1(T17N) or Rac3(T17N) cause a signif-
icant decrease in adhesion when expressed in the high meta-
static MDA-MB-435α6HG6 variant (Fig. 6a,d).
Figure 4
Inhibition of Rho GTPases, Rac, or Cdc42 in migration of the high metastatic MDA-MB-435α6HG6 cell variant Inhibition of Rho GTPases, Rac, or Cdc42 in migration of the high metastatic MDA-MB-435α6HG6 cell variant. (a) MDA-MB-435α6HG6 cells were 
treated with vehicle or 2 ng/ml toxin B for 24 h and subjected to a basement membrane haptotaxis assay. Cells migrating to the underside of the 
membrane were stained with propidium iodide and counted under 400× Magnification. (b) MDA-MB-435α6HG6 cells transiently expressing vector 
alone or myc-Cdc42(T17N) were subjected to a basement membrane haptotaxis assay. Cells migrating to the underside of the membrane were 
stained with propidium iodide and counted under 400× Magnification. Equal loading was confirmed by a total actin blot, ectopic myc-Cdc42(T17N) 
expression confirmed by western blotting with anti-Cdc42 or anti-myc. (c) MDA-MB-435α6HG6 cells transiently expressing vector alone, myc-
Rac1(T17N), or myc-Rac3(T17N) were subjected to a basement membrane haptotaxis assay. Bars represent ±SEM; equal loading was confirmed 
by total actin blot. Myc-Rac1(T17N) and myc-Rac3(T17N) expression were confirmed by western blotting with anti-Rac or anti-myc. Data are 
expressed as mean ±SEM of three independent experiments. A star denotes statistical significance from control (P < 0.05, calculated from paired t-
tests).Available online http://breast-cancer-research.com/content/7/6/R965
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A requirement of malignant cells to undergo metastasis is to
acquire the ability to penetrate the surrounding extracellular
matrix in order to migrate to distant tissues [22]; thus, we
tested the effect of Rac mutants on both migration and inva-
sion in vitro. Expression of either myc-tagged Rac1(G12V) or
Rac3(G12V) caused a significant increase in migration and
invasion when expressed in the low metastatic variant (Fig.
6b,c). Surprisingly, Rac3(G12V) expressing cells invaded
through basal lamina 1.5 times more than cells expressing
Rac1(G12V); however, this difference was a trend and not
statistically significant (Fig. 6c). Invasion of highly metastatic
cells expressing dominant negative Rac1(T17N) or
Rac3(T17N) was significantly diminished compared to the
vector alone control (Fig. 6e). Furthermore, migration was also
significantly reduced in highly metastatic cells expressing
dominant negative mutants of Rac isoforms compared to vec-
tor alone control (Fig. 3b). Taken together, these data
establish the efficacy of both Rac1 and Rac3 in human breast
cancer progression.
Discussion
The present study demonstrates a strong correlation between
the invasive phenotype, increased Rac activity, and the
increased metastatic efficiency of the variants of the MDA-MB-
435 metastatic human breast cancer cell line. These cell vari-
ants reflect the relative ability to form lung metastases from
established mammary tumors in the nude mouse model of
experimental metastasis.
The invasive phenotype, characterized by extensive cross-
linked actin networks and increased lamellipodial expression,
has long been associated with increased motility and invasion
[23]. More recently, this specific phenotype has been linked to
cells with an inherent ability to metastasize [1,2]. Our study
adds to this field by correlating an increasingly aggressive
phenotype with an increase of metastatic efficiency in a panel
of metastatic cell variants. Oncogenically mutated forms of
Rac and Rho proteins have not been found in human cancer
cells; instead, it is thought that amplification of Rho family pro-
teins or activation of their upstream regulators, such as
exchange factors, contribute to the ability of these GTPases to
influence the transformed phenotype [4,7,24]. Therefore, the
observed variation in Rac activity of the MDA-MB-435 cell var-
iants is probably due to disparities in the activity of upstream
regulators of Rac.
We also show that an increase in focal adhesion number per
cell area correlates directly with metastatic efficiency. The
physiological significance of this finding is less clear due to
discrepancies in the literature on the relative contribution of
focal adhesion number to cell motility. Some studies assert
that a simple redistribution or relocalization of focal adhesions
is sufficient to alter motility signaling pathways to the point of
Figure 5
Ectopic dominant active Rac(G12V) expression in low metastatic variant MDA-MB-435Br1 Ectopic dominant active Rac(G12V) expression in low metastatic variant MDA-MB-435Br1. Confocal DIC (Differential Interference Contrast) and 
fluorescent microscopy was performed on MDA-MB-435Br1 cell variant stably expressing vector alone, myc-Rac1(G12V), or myc-Rac3(G12V). 
Cells were plated on glass coverslips, fixed in 3.7% formaldehyde and permeablized with 0.2% Triton X-100. Actin was then visualized with rhodam-
ine phalloidin and focal adhesions were visualized with an anti-p-tyro antibody followed by an FITC conjugate.Breast Cancer Research    Vol 7 No 6    Baugher et al.
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invasive transformation [25,26]. Other studies maintain that
increased tyrosine phosphorylation and focal adhesion expres-
sion are correlated with the progression to an invasive cell
phenotype [19]. Our study shows that the increased number
of focal adhesions in highly metastatic cells is likely to be
located in the lamellipodia, which are also increased in the
more highly metastatic variants. Thus, we conclude that an
increased number of focal adhesions is correlative with
increased invasion. Rac activation can lead to actin polymeri-
zation and lamellipodia formation, which in turn can lead to the
creation of focal adhesions. Focal adhesion formation can then
activate Rac, which creates a positive feedback loop that,
when disregulated, can lead to increased motility and invasion
[27]. This positive feedback loop is most likely what is being
activated in these cell variants to produce the specific pheno-
type and increased focal adhesion patterns. Supporting this
hypothesis is the increased Rac activity found in the more met-
astatic cell variants.
Surprisingly, we show in this study that Cdc42 is not activated
in any of the cell variants, including the variant with the highest
metastatic efficiency. This finding is unexpected because
Cdc42 is essential to cellular motility via WASP (Wiskott
Aldrich Syndrome Protein), Arp2/3 (actin-related protein), and
subsequent actin polymerization and filopodia formation [28].
Furthermore, Cdc42 has also been implicated in both the
transformation and malignant progression of cancer [6,29].
Additionally, we show that blocking all Cdc42 activity cannot
prevent the most metastatic variant from haptotaxing to basal
lamina. This finding suggests that Cdc42 is not vital for malig-
nant invasion in breast cancer, perhaps because Rac and
Cdc42 are redundant in many of the roles they play in cell
motility. For example, both Rac and Cdc42 can activate Arp2/
3 to result in actin polymerization. Whereas Cdc42 activates
Arp2/3 through WASP, Rac activates Arp2/3 through WAVE
(WASP family verprolin homolog) [28].
In this study, we also demonstrate the efficacy of both the
Rac1 and Rac3 isoforms in the malignant progression of
human breast cancer. Because Rac1 and Rac3 both have
been implicated in breast cancer [5,11,30], we carried out a
comparative study between the two isoforms. We found that
blocking Rac activity by expressing dominant negative muta-
tions of Rac1 or Rac3 significantly curtailed cellular processes
critical for metastatic progression in vitro. Moreover, we found
that augmenting endogenous Rac activity by expressing dom-
inant active Rac1 or Rac3 led to a significant increase in adhe-
sion, migration, and invasion. Taken together, these data
substantiate not only a vital role for Rac1 in cell functions rele-
vant for breast cancer metastasis, but also a vital role for Rac3.
In fact, expression of a dominant active Rac3 in the MDA-MB-
435Br1 low metastatic cell variant increased invasion through
basal lamina 1.5 times compared to expression of dominant
active Rac1. This difference suggests an enhanced ability of
Figure 6
Effects of mutant Rac isoforms on metastatic properties in vitro Effects of mutant Rac isoforms on metastatic properties in vitro. MDA-MB-435Br1 cells transiently transfected with vector alone, myc-Rac1(G12V), 
or myc-Rac3(G12V), were subjected to (a) adhesion, (b) haptotaxis, and (c) invasion assays. MDA-MB-435α6HG6 cells transiently expressing vec-
tor alone, myc-Rac1(T17N), or myc-Rac3(T17N), were subjected to (d) adhesion, and (e) invasion assays. Cells were counted under 200× Magnifi-
cation for adhesions assays, and 400× Magnification for haptotaxis and invasion assays. Y-axis represents the number of cells/field for at least 20 
microscopic fields per variant. Bars represent standard error of the mean, and are representative of at least three separate experiments. An asterix 
indicates a statistically significant difference compared to the control, vector alone, as determined by a paired Student's t-test (P < 0.05).Available online http://breast-cancer-research.com/content/7/6/R965
R973
the cells expressing Rac3(G12V) to invade, perhaps by a
more efficient degradation of the extracellular matrix compared
to the cells expressing Rac1(G12V). Because we found that
expression of dominant active Rac1 or Rac3 results in a similar
motile phenotype, it is possible that Rac3 is more efficient at
activating proteins that degrade extracellular matrix proteins,
or matrix metalloproteinases, than is Rac1.
Rac1 and Rac3 differ in their carboxyl terminus region, which
is essential for subcellular localization [8]. Even though protein
function is likely partially redundant due to the homology of the
downstream effector loops, these proteins have been found to
differ in their localization within certain types of cells [10]. Dif-
ferential subcellular localization can place proteins in the prox-
imity of different signaling cascades, resulting in differential
function. More experiments are needed, however, to show that
Rac1 actually acts differently to Rac3 with respect to human
breast cancer.
Studies have also demonstrated that, in addition to the Rac
proteins, Rho proteins, especially RhoC, may contribute to
breast cancer cell invasion. RhoC was demonstrated to be
overexpressed in the human inflammatory breast cancer cell
line SUM 149 and transient inhibition of RhoC in inflammatory
breast cancer cells by treatment with farnesyl transferase
inhibitors reduced invasion and motility in vitro, whereas RhoC
overexpression in mammary epithelial cells resulted in a signif-
icant increase in cell migration [31]. Interestingly, the most
metastatic MDA-MB-435 variant demonstrated the highest
Rho activity (data not shown) and future studies will include an
analysis of Rho isoforms of the metastatic phenotype in breast
cancer.
Conclusion
We found a direct correlation between increased metastatic
potential and increased endogenous Rac activity in a panel of
metastatic human breast cancer cells that vary in their ability to
form secondary metastases in an in vivo model. By using vari-
ants of the same cell line, we have minimized genetic variation.
It remains to be investigated, however, whether or not similar
results will be observed in other cell lines with different genetic
backgrounds.
The research presented here establishes a direct role for Rac3
in cell functions relevant for breast cancer progression. We
found that Rac3 activation alone can significantly increase in
vitro  metastatic properties in human breast cancer cells.
Currently, we are testing the hypothesis that Rac3 activation
alone can increase breast cancer metastasis in vivo by using
the nude mouse model of experimental metastasis.
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